cloprostenol has been researched along with Osteoporosis* in 2 studies
2 other study(ies) available for cloprostenol and Osteoporosis
| Article | Year |
|---|---|
Synthesis and biological evaluation of prostaglandin-F alkylphosphinic acid derivatives as bone anabolic agents for the treatment of osteoporosis.
A series of novel C(1) alkylphosphinic acid analogues of the prostaglandin-F family have been evaluated at the eight human prostaglandin receptors for potential use in the treatment of osteoporosis. Using molecular modeling as a tool for structure-based drug design, we have discovered that the phosphinic acid moiety (P(O)(OH)R) behaves as an isostere for the C(1) carboxylic acid in the human prostaglandin FP binding assay in vitro and possesses enhanced hFP receptor selectivity when compared to the parent carboxylic acid. When evaluated in vivo, the methyl phosphinic acid analogue (4b) produced a bone anabolic response in rats, returning bone mineral volume (BMV) [corrected], to intact levels in the distal femur in the ovariectomized rat (OVX) model. These results suggest that prostaglandins of this class may be useful agents in the treatment of diseases associated with bone loss. Topics: Absorptiometry, Photon; Amino Acid Sequence; Animals; Binding, Competitive; Bone and Bones; Bone Density; COS Cells; Dinoprost; Female; Humans; Models, Molecular; Molecular Sequence Data; Osteoporosis; Ovariectomy; Phosphinic Acids; Prostaglandins F, Synthetic; Radioligand Assay; Rats; Rats, Sprague-Dawley; Receptors, Prostaglandin; Structure-Activity Relationship; Tomography, X-Ray Computed; Transfection | 2001 |
Design and synthesis of 13,14-dihydro prostaglandin F(1alpha) analogues as potent and selective ligands for the human FP receptor.
The in vitro evaluation of a new class of potential bone anabolic agents for the treatment of osteoporosis is described. These compounds are potent and selective ligands for the human prostaglandin F receptor (hFP receptor). The compounds lack the olefin unsaturation required for potency in the natural ligand PGF(2)(alpha) yet retain binding affinity for the hFP receptor in the nanomolar to micromolar range. Removal of the alkenes also results in a better selectivity ratio for the hFP receptor over the other prostaglandin receptors tested. A rationale for the selectivity differences of various analogues, based on ligand docking experiments to a putative hFP receptor model, is also described. Topics: Animals; Binding, Competitive; COS Cells; Drug Design; Humans; Ligands; Models, Molecular; Osteoporosis; Prostaglandins F; Radioligand Assay; Rats; Receptors, Prostaglandin; Stereoisomerism; Structure-Activity Relationship | 2000 |